Source:http://linkedlifedata.com/resource/pubmed/id/10576130
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1999-12-8
|
| pubmed:abstractText |
We evaluated the frequency of and reasons for discontinuation of protease inhibitor therapy in a cohort of HIV-infected patients in a prospective observational study. We included 230 HIV-infected patients who had started protease inhibitor therapy between November 1996 and July 1997. Mean baseline CD4 count was 138 cells/microl and HIV-RNA 4.5 log10. Forty-five percent of patients had prior AIDS and 77% had been treated with nucleoside analogues. Saquinavir-treated patients were at a less advanced stage of HIV disease. Overall, 41.3% of patients discontinued therapy, and their last HIV-RNA measured higher than that of patients who continued therapy: 4.07 vs. 2.70 log10 (p < 0.0001). Reasons for discontinuation of therapy were poor adherence (including abandonment) (18.6%), drug intolerance (12.1%), virological failure (7%) and physician decision (3.5%). In a multivariate model, factors associated with drug discontinuation were not taking indinavir (OR 0.26, 95% CI 0.12-0.59) and being pretreated with nucleoside analogues (OR 3.42, 95% CI 1.58-7.42). We concluded that in routine clinical practice a high proportion of patients discontinued protease inhibitors during the first 6 months of therapy, the main reason being the patient's own decision (abandonment or poor adherence). Psychological support and counselling are warranted in patients when initiating protease inhibitor therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0036-5548
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
495-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10576130-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:10576130-Adult,
pubmed-meshheading:10576130-Analysis of Variance,
pubmed-meshheading:10576130-Cohort Studies,
pubmed-meshheading:10576130-Counseling,
pubmed-meshheading:10576130-Drug Administration Schedule,
pubmed-meshheading:10576130-Female,
pubmed-meshheading:10576130-HIV Infections,
pubmed-meshheading:10576130-HIV Protease Inhibitors,
pubmed-meshheading:10576130-Humans,
pubmed-meshheading:10576130-Indinavir,
pubmed-meshheading:10576130-Male,
pubmed-meshheading:10576130-Physician's Practice Patterns,
pubmed-meshheading:10576130-Prospective Studies,
pubmed-meshheading:10576130-Ritonavir,
pubmed-meshheading:10576130-Saquinavir,
pubmed-meshheading:10576130-Treatment Refusal,
pubmed-meshheading:10576130-Viral Load
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice.
|
| pubmed:affiliation |
Infectious Diseases Service, Ciutat Sanitaria de Bellvitge, University of Barcelona, Spain.
|
| pubmed:publicationType |
Journal Article
|